Next Era Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
- Paid Up Capital ₹ 0.10 M
- Company Age 3 Year, 2 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Profit Growth 327.77%
- Ebitda 395.43%
- Net Worth 52.74%
- Total Assets 3523.01%
About Next Era Pharmaceuticals
Next Era Pharmaceuticals Private Limited (NEPPL) is a Private Limited Indian Non-Government Company incorporated in India on 17 December 2021 (Three years and two months 10 days old ). Its registered office is in Indore, Madhya Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Pawan Arora and Dharmik Arora serve as directors at the Company.
Company Details
- Location
Indore, Madhya Pradesh, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U52395MP2021PTC058846
- Company No.
058846
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Dec 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Gwalior
Industry
Who are the key members and board of directors at Next Era Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Pawan Arora  | Director | 17-Dec-2021 | Current |
| Dharmik Arora | Director | 17-Dec-2021 | Current |
Financial Performance of Next Era Pharmaceuticals.
Next Era Pharmaceuticals Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 327.77% increase in profit. The company's net worth Soared by an impressive increase of 52.74%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Next Era Pharmaceuticals?
Unlock access to Next Era Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Next Era Pharmaceuticals?
Next Era Pharmaceuticals has a workforce of 0 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Next Era Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Next Era Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.